Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNYSE:CYBNNASDAQ:LTRNNASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.44+4.3%$1.48$0.95▼$5.17$155.93M0.421.19 million shs668,869 shsCYBNCybin$6.50-1.8%$6.93$4.81▼$14.44$139.60M0.59238,394 shs172,842 shsLTRNLantern Pharma$3.54-2.2%$3.52$2.55▼$7.21$38.18M1.6366,078 shs10,947 shsPBYIPuma Biotechnology$3.21+4.2%$3.13$2.23▼$5.20$159.32M1.29440,511 shs327,172 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+7.46%+2.86%-40.00%+5.88%CYBNCybin0.00%-7.01%+14.24%-33.94%+1,757.14%LTRNLantern Pharma0.00%-1.39%+18.39%-24.20%-42.44%PBYIPuma Biotechnology0.00%+7.00%+10.69%+15.05%-33.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics3.1665 of 5 stars3.63.00.00.03.41.71.3CYBNCybin2.4025 of 5 stars3.50.00.00.02.70.81.3LTRNLantern Pharma1.868 of 5 stars3.53.00.00.00.60.01.3PBYIPuma Biotechnology3.7695 of 5 stars3.52.00.00.01.83.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.67710.19% UpsideCYBNCybin 3.00Buy$86.001,223.08% UpsideLTRNLantern Pharma 3.00Buy$25.00606.21% UpsidePBYIPuma Biotechnology 3.00Buy$7.00118.07% UpsideCurrent Analyst Ratings BreakdownLatest LTRN, PBYI, CYBN, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025LTRNLantern PharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/18/2025ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight3/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.003/7/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/4/2025ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/28/2025PBYIPuma BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/13/2025CYBNCybinHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$190.00 ➝ $150.002/12/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $73.00(Data available from 5/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M8.33N/AN/A$2.22 per share0.65CYBNCybinN/AN/AN/AN/A$10.83 per shareN/ALTRNLantern PharmaN/AN/AN/AN/A$3.76 per shareN/APBYIPuma Biotechnology$230.47M0.69$0.77 per share4.19$1.12 per share2.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.51N/AN/AN/A-136.65%-40.26%-31.71%5/6/2025 (Estimated)CYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/ALTRNLantern Pharma-$15.96M-$1.93N/AN/AN/AN/A-56.91%-51.17%5/8/2025 (Estimated)PBYIPuma Biotechnology$21.59M$0.616.698.45N/A9.56%41.60%10.71%5/8/2025 (Estimated)Latest LTRN, PBYI, CYBN, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LTRNLantern Pharma-$0.49N/AN/AN/AN/AN/A5/8/2025Q1 2025PBYIPuma Biotechnology$0.02N/AN/AN/A$44.55 millionN/A5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19N/AN/AN/A$3.55 millionN/A3/27/2025Q4 2024LTRNLantern Pharma-$0.51-$0.54-$0.03-$0.54N/AN/A2/27/2025Q4 2024PBYIPuma Biotechnology$0.10$0.39+$0.29$0.39$52.50 million$59.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A7.037.03CYBNCybinN/A24.2424.24LTRNLantern PharmaN/A8.318.31PBYIPuma Biotechnology0.461.421.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CYBNCybin17.94%LTRNLantern Pharma28.62%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%CYBNCybin15.00%LTRNLantern Pharma7.31%PBYIPuma Biotechnology23.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million66.86 millionOptionableCYBNCybin5021.48 million17.96 millionNot OptionableLTRNLantern Pharma2010.79 million10.00 millionOptionablePBYIPuma Biotechnology20049.63 million37.45 millionOptionableLTRN, PBYI, CYBN, and ACRS HeadlinesRecent News About These CompaniesPuma Biotechnology (NASDAQ:PBYI) Cut to "Buy" at StockNews.comMay 5 at 2:35 AM | marketbeat.comZacks Research Issues Pessimistic Forecast for PBYI EarningsMay 4 at 7:15 AM | marketbeat.comAcorn Capital Advisors LLC Purchases Shares of 2,450,711 Puma Biotechnology, Inc. (NASDAQ:PBYI)May 4 at 7:13 AM | marketbeat.comJPMorgan Chase & Co. Increases Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)May 4 at 3:02 AM | marketbeat.comZacks Research Brokers Reduce Earnings Estimates for PBYIMay 4 at 1:33 AM | americanbankingnews.comQ1 EPS Forecast for Puma Biotechnology Boosted by AnalystMay 3 at 8:36 AM | marketbeat.comQ1 EPS Forecast for Puma Biotechnology Raised by AnalystMay 3 at 3:29 AM | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Lowered to Buy Rating by StockNews.comMay 3 at 2:39 AM | americanbankingnews.comPuma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should KnowApril 30, 2025 | zacks.comEr-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer PatientsApril 30, 2025 | globenewswire.comPuma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025April 28, 2025 | businesswire.comStockNews.com Upgrades Puma Biotechnology (NASDAQ:PBYI) to "Strong-Buy"April 27, 2025 | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to Strong-Buy at StockNews.comApril 27, 2025 | marketbeat.comPuma Biotechnology (PBYI) to Release Quarterly Earnings on ThursdayApril 26, 2025 | marketbeat.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial ResultsApril 24, 2025 | businesswire.comEversept Partners LP Decreases Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)April 24, 2025 | marketbeat.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?April 23, 2025 | zacks.comIs the Options Market Predicting a Spike in Puma Biotechnology Stock?April 21, 2025 | zacks.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to "Strong-Buy" at StockNews.comApril 18, 2025 | marketbeat.comKennedy Capital Management LLC Buys 216,329 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)April 16, 2025 | marketbeat.comPuma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline PotentialApril 11, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTRN, PBYI, CYBN, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.44 +0.06 (+4.35%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 05/2/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Cybin NYSE:CYBN$6.50 -0.12 (-1.81%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$6.48 -0.01 (-0.23%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Lantern Pharma NASDAQ:LTRN$3.54 -0.08 (-2.21%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.78 +0.24 (+6.64%) As of 05/2/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Puma Biotechnology NASDAQ:PBYI$3.21 +0.13 (+4.22%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.22 +0.01 (+0.44%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Why Energy Stocks Like Exxon and Hess Are Back in Focus Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Western Digital: Is the Storage Sector Set for a Rebound? Wingstop Stock Jumps on Q1 Beat, Expansion Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
